Ocugen (OCGN) Preferred Stock Liabilities (2018 - 2019)
Ocugen's (OCGN) quarterly Preferred Stock Liabilities came in at $64347.0 in Q2 2019, down 90.99% YoY from $714041.0 in Q2 2018, and down 98.05% on a QoQ basis from $3.3 million in Q4 2018.
Powered by 
Analysis
Ocugen (OCGN) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Ocugen (OCGN) has 2 years of Preferred Stock Liabilities data on file, last reported at $64347.0 in Q2 2019.
- Quarterly Preferred Stock Liabilities fell 90.99% year-over-year to $64347.0 in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $64347.0 (down 90.99% YoY) and the FY2018 annual result came in at $3.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities declined to $64347.0 in Q2 2019, from $3.3 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $3.3 million in Q4 2018 to a low of $64347.0 in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2019 | 64,347.00 |
| Dec 31, 2018 | 3.29 Mn |
| Jun 30, 2018 | 714,041.00 |